All In Biotech

Drug Trial Radar · NCT01820260

Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis

Safety and Efficacy of Escalating Doses of Ingenol Mebutate Once Daily for Two or Three Consecutive Days When Used on Full Face, Full Balding Scalp or Approximately 250 cm2 on the Chest in Subjects With Actinic Keratosis

Last checked: Nov 20, 2026Latest source record: Mar 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 395 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

395

Actual

Start

Apr 2013

Primary completion

Aug 2014

Study completion Aug 2014

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Mar 28, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To identify the Maximum Tolerated Dose levels of ingenol mebutate gel after once daily treatment for 2 or 3 consecutive days and to evaluate efficacy of ingenol mebutate gel in different doses after once daily treatment for 2 or 3 consecutive days compared to vehicle gel

Conditions

  • Actinic Keratosis

Interventions

  • Ingenol mebutate gelDrug

  • placeboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: To Identify the Maximum Tolerated Dose (MTD) Levels After Once Daily Treatment for 2 or 3 DaysTime frame: 8 days after initial treatment
  2. Part 2: Number of Subjects With Complete Clearance of AKsTime frame: 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Laser & Skin Surgery Center of Inidana

    Carmel, Indiana

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.